Neovascular age-related macular degeneration Trials in Baltimore, United States
Conditions / Neovascular age-related macular degeneration / Baltimore, United States
Neovascular age-related macular degeneration is a medical condition with active clinical research programs worldwide.
22 total trials for this combination
Showing top 10 of 22 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03683251 | Extension Study for the Port Delivery System With Ranibizumab (Portal) | RECRUITING | — |
| NCT04704921 | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | ACTIVE_NOT_RECRUITING | — |
| NCT07007065 | Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) | RECRUITING | — |
| NCT03345082 | A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD | COMPLETED | PHASE2 |
| NCT04777201 | A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration | COMPLETED | PHASE3 |
| NCT03683251 | Extension Study for the Port Delivery System With Ranibizumab (Portal) | RECRUITING | — |
| NCT02418754 | Study of Intravitreal REGN2176-3 in Participants With Neovascular (Wet) Age-Related Macular Degeneration (AMD) | TERMINATED | PHASE2 |
| NCT04704921 | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | ACTIVE_NOT_RECRUITING | — |
| NCT04423718 | Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye | COMPLETED | PHASE3 |
| NCT04757610 | OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) | TERMINATED | PHASE3 |